IRIBHM

What IRIBHM does

IRIBHM (Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire) Jacques E. Dumont is a multidisciplinary academic biomedical research institute located at the Université Libre de Bruxelles (ULB) Campus Erasme in Brussels, Belgium. The institute conducts fundamental and translational research across five primary domains — signal transduction, developmental biology, neuroscience, cancer biology, and computational biology — using wet-lab platforms including organoid technology, CRISPR/Cas9 gene editing screens on embryonic stem cell-derived organoids, 3D vascularized microfluidic organ-on-chip models, transgenic zebrafish lines, and a mass spectrometry/proteomics core facility. Its primary internal users are its own principal investigators, postdoctoral researchers, PhD students, and staff scientists (21 listed core personnel), and it serves the broader academic research community through publications (1,401 cumulative), a recurring Science Web-in-hour seminar series, PhD and postdoctoral training programs, and international collaborations.

The institute operates a non-commercial business model. It does not sell products, license a commercial catalog, or operate as a venture-backed entity. Funding flows from university allocations (ULB), Belgian public research grants (F.R.S.-FNRS, ARC, Welbio and similar competitive programs), and supplemental donations from two non-profit supporter associations: AMIR (Academic Medical Interdisciplinary Research Association) and ARBD (Association Recherche Biomédicale et Diagnostic). Research outputs are disseminated through peer-reviewed publications, conference presentations, formal collaborative research agreements (including a partnership with Nanyang Technological University Singapore on cancer organ-on-chip models), and technology transfer through university channels.

Recent research outputs illustrate the institute's translational positioning: development of transplantable human thyroid organoids from embryonic stem cells capable of rescuing hypothyroidism, and identification of CDK4/6 inhibitor immune-related vulnerabilities in esophageal cancer. Distribution is purely academic and global in geographic scope. The institute is governed by a Director (Sabine Costagliola) and Vice Directors (Valérie Wittamer, Benjamin Beck), with a documented succession lineage of former directors including Jacques Dumont, Gilbert Vassart, and Marc Parmentier.

Name

IRIBHM

Legal name

Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire

Website

https://iribhm.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

IRIBHM Jacques E. Dumont is a multidisciplinary academic biomedical research institute at Université Libre de Bruxelles in Brussels, Belgium, conducting fundamental and translational research in signal transduction, development, neuroscience, cancer, and computational biology for the academic research community.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Public Research Funding: Core funding from Université Libre de Bruxelles (ULB), F.R.S.-FNRS (Fonds de la Recherche Scientifique), and other Belgian public research funding bodies.
2. Research Associations (AMIR, ARBD): Supplemental funding from non-profit associations AMIR (Academic Medical Interdisciplinary Research Association) and ARBD (Association Recherche Biomédicale et Diagnostic) that support IRIBHM research in complement to public funding.
3. Collaborative Research Grants: Project-based funding from national and international research grants including ARC, Welbio, and other competitive research funding programs.
4. Technology Transfer (potential): Potential licensing revenue from research discoveries and innovations developed at the institute.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

IRIBHM is a multidisciplinary biomedical research institute that conducts fundamental and translational research in signal transduction, developmental biology, neuroscience, cancer biology, and computational biology. It operates multiple PI-led research labs and core research facilities (including a Mass Spectrometry and Proteomics Platform), develops organoid and organ-on-chip disease models, and delivers research training through PhD and postdoctoral programs. The institute also disseminates findings through peer-reviewed publications, scientific seminars, and collaborations with international research partners.

Product overview

IRIBHM Jacques E. Dumont is a multidisciplinary research institute at Université Libre de Bruxelles (ULB) in Belgium. The institute conducts fundamental and translational biomedical research across several key areas: signal transduction, development, neuroscience, cancer biology, and computational biology. The institute operates various research labs and core facilities, including a Mass Spectrometry and Proteomics Platform, and maintains active research programs in organoids (thyroid, intestinal, tumor models), extra-embryonic development, immunology, and molecular genetics. IRIBHM also hosts educational programs including the Science Web-in-hour Biomedical Research Seminars series. The institute has published over 1,400 publications and supported 283 doctoral theses, reflecting its substantial contribution to biomedical science.

Differentiator

Problem solved

Functional benefit

Products and services

• Mass Spectrometry and Proteomics Platform

Quantifiable outcome

• 1,401 publications and 283 theses
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Nanyang Technological University Singapore (Andrea Pavesi Lab)coreStrategic or Co-development PartnerCollaboration on vascularized organ-on-chip platform for cancer research. The Andrea Pavesi Lab at NTU Singapore worked with IRIBHM researchers (Xavier Bisteau Lab) on combining CDK4/6 inhibition studies with organ-on-chip tumor models to test immune cell recruitment and immunotherapy responses.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• VIB (Vlaams Instituut voor Biotechnologie): Belgian life sciences research institute with multiple research centers covering cancer, neuroscience, and developmental biology. Highly comparable to IRIBHM as a Belgian, university-affiliated biological research organisation with overlapping thematic areas.
• Babraham Institute: UK research institute focused on epigenetics, signalling, and immunology. Similar scientific scope to IRIBHM, particularly in signal transduction and developmental biology research.
• Centre for Genomic Regulation (CRG): Barcelona-based biomedical research institute conducting fundamental research in gene regulation, cell biology, and disease. Comparable in scale and mission to IRIBHM as an interdisciplinary, university-affiliated European research centre.
• Whitehead Institute for Biomedical Research: MIT-affiliated biomedical research institute with a mission of fundamental research in cancer, developmental biology, and regenerative medicine. Comparable to IRIBHM in research focus and academic affiliation model.
• Max Planck Institute for Molecular Genetics: German Max Planck Institute focused on molecular genetics, genomics, and developmental biology. Comparable to IRIBHM in research scope and as a publicly funded basic research entity.
• Hubrecht Institute (KNAW): Dutch developmental biology and stem cell research institute, internationally renowned for organoid technology pioneered by Hans Clevers. Directly comparable to IRIBHM's organoid and stem cell research programmes.

Broad incumbents

• EMBL (European Molecular Biology Laboratory): Pan-European intergovernmental research organisation for molecular life sciences. Comparable to IRIBHM in fundamental life sciences research but significantly larger, with multiple sites and a broader mandate.
• Francis Crick Institute: UK biomedical research institute covering cancer, neuroscience, and developmental biology. Comparable to IRIBHM in research focus but substantially larger in scale, headcount, and funding capacity.
• Institut Pasteur: French biomedical research institution with a global network focused on infectious disease, immunology, and developmental biology. Comparable to IRIBHM in research disciplines but much larger and with international affiliates.
• Weizmann Institute of Science: Israeli multidisciplinary research institution with significant life sciences research across cancer, developmental biology, and neuroscience. Comparable to IRIBHM in research scope but considerably larger and more established.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/iribhm

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IRIBHM